Woodcock Said To Have Guided Hydroxychloroquine EUA In ‘Brokered Compromise’ To Limit Use
Executive Summary
In whistleblower complaint, Rick Bright claims FDA Commissioner Hahn advocated for distributing hydroxychloroquine to pharmacies across the US, a departure from the approved emergency use authorization. Bright's complaint paints CDER Director Woodcock in a favorable light, saying she helped avoid an expanded access IND protocol for the potential coronavirus treatment.
You may also be interested in...
House Coronavirus Panel Has Questions For Former FDA Commissioner Hahn On Trump Interference
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.
Former FDA Commissioner Hahn Faces Questions From House On Trump Interference, Other COVID Issues
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.
Could A COVID-19 Vaccine Gain EUA Without Sponsor Cooperation?
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.